AbbVie Inc. stock rises Monday, still underperforms market
AbbVie Inc. closed $6.12 short of its 52-week high ($199.95), which the company reached on September 3rd.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
hrexecutive9h
Creating culture from the ground up: How AbbVie did it
After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...
Buy Rating on Glaukos: iDose’s Market Potential and Strategic Advantages Outshine Ripple’s RTC-620
BTIG analyst Ryan Zimmerman maintained a Buy rating on Glaukos (GKOS – Research Report) yesterday and set a price target of $139.00. Ryan ...
Pharmabiz14h
EMA committee recommends marketing approval for AbbVie’s mirvetuximab soravtansine for the treatment of certain adult ovarian cancer
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
Taiwan News15h
Renal Anemia Market Is Likely to Experience a Tremendous Growth in near Future
Report Ocean has released a market research report on the Renal Anemia Market, covering 150+ countries and analyzing over 1,00000 published and forthcoming reports per year. The report, prepared by ...
BioSpace18h
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...